[Ip-health] Study on global insulin market launched

Marg Ewen Marg at haiglobal.org
Fri Jan 16 02:54:13 PST 2015


Dear members of Ip-health

Global study launched to examine barriers to accessing insulin and propose interventions to improve access for 100 million people world-wide in need of this medicine.

Health Action International today launched an innovative global study to identify the causes of poor access to insulin and deliver concrete, data-driven solutions to better ensure universal access to this life-saving medicine.

The three-year 'Addressing the Challenges and Constraints of Insulin Sources and Supply' (ACCISS) Study will result in a comprehensive, novel evidence-base on the global insulin market. ACCISS will examine the type, extent and impact of barriers that limit insulin access. The study will also assess existing initiatives designed to improve insulin access and determine if lessons may be gleaned from them.  Based on the evidence, interventions to break down barriers to insulin access will be developed.

The study is being led by David Beran (Geneva University Hospitals and University of Geneva), Marg Ewen (Health Action International) and Richard Laing (Boston University) with support from an extensive advisory and technical team. The study is being funded by a US$1.25 million grant from The Leona M. and Harry B. Helmsley Charitable Trust.

More information about the study is available on Health Action International's website http://www.haiweb.org/05_focus_ACCISS.htm

Press release:  http://www.haiweb.org/16012015/Press_release-CCISS_Study-Launch.pdf

Blog: http://haistaffblog.blogspot.nl/2015/01/hai-launches-innovative-global-study-to.html

Regards
Marg Ewen

Coordinator, Global Projects (Pricing)
Health Action International
Overtoom 60/II
1054 HK Amsterdam
The Netherlands
Tel: +31 20 489 1846 (direct), +31 20 683 3684 (office)
Web site: http://www.haiglobal.org<http://www.haiweb.org/>

Health Action International (HAI) is an independent, global network working to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.




More information about the Ip-health mailing list